Valemetostat tosylate
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, B-Cell
Conditions
Lymphoma, B-Cell
Trial Timeline
Jun 11, 2021 → Oct 1, 2026
NCT ID
NCT04842877About Valemetostat tosylate
Valemetostat tosylate is a phase 2 stage product being developed by Daiichi Sankyo for Lymphoma, B-Cell. The current trial status is active. This product is registered under clinical trial identifier NCT04842877. Target conditions include Lymphoma, B-Cell.
What happened to similar drugs?
18 of 20 similar drugs in Lymphoma, B-Cell were approved
Approved (18) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07303387 | Phase 2 | Recruiting |
| NCT04842877 | Phase 2 | Active |
| NCT04703192 | Phase 2 | Active |
| NCT04102150 | Phase 2 | Completed |
Competing Products
20 competing products in Lymphoma, B-Cell